SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001169245-22-000103
Filing Date
2022-10-24
Accepted
2022-10-24 08:02:10
Documents
14
Period of Report
2022-10-23
Items
Item 1.03: Bankruptcy or Receivership
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K phas-20221023.htm   iXBRL 8-K 38299
2 EX-99.1 phasebioplansfornear-terms.htm EX-99.1 19993
6 phasebio2020logo.jpg GRAPHIC 27705
  Complete submission text file 0001169245-22-000103.txt   247514

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT phas-20221023.xsd EX-101.SCH 1902
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT phas-20221023_lab.xml EX-101.LAB 25848
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT phas-20221023_pre.xml EX-101.PRE 13581
8 EXTRACTED XBRL INSTANCE DOCUMENT phas-20221023_htm.xml XML 11435
Mailing Address 1 GREAT VALLEY PARKWAY SUITE 30 MALVERN PA 19355
Business Address 1 GREAT VALLEY PARKWAY SUITE 30 MALVERN PA 19355 (610) 981-6500
PhaseBio Pharmaceuticals Inc (Filer) CIK: 0001169245 (see all company filings)

IRS No.: 030375697 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38697 | Film No.: 221324861
SIC: 2834 Pharmaceutical Preparations